GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan’s Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-related outcomes.
The vaccine was previously approved in Japan for individuals aged 60 and older.
"This approval reflects our ambition to protect people at increased risk from the severe consequences of RSV infection,” GSK chief scientific officer Tony Wood said in a statement.
“Adults aged 50-59 with certain underlying medical conditions can face debilitating consequences from RSV, so we are pleased to offer those in Japan a vaccine for the first time."
Respiratory Syncytial Virus (RSV) is a common virus that can cause severe illness in adults with underlying health conditions such as COPD, asthma, and chronic heart failure.